JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|20|9|1147-1161

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.20, Iss.9, 2013-03, pp. : 1147-1161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

JAK2 inhibitors in the treatment of myeloproliferative neoplasms

By Tibes Raoul   Bogenberger James M   Geyer Holly L   Mesa Ruben A  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1755-1774

Informa Healthcare

Access to resources Recommend Favorite

New JAK2 inhibitors for myeloproliferative neoplasms

By Quintáás-Cardama Alfonso   Verstovsek Srdan  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 7, 2011-07 ,pp. : 961-972

Informa Healthcare

Access to resources Recommend Favorite

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

By  

Current Medicinal Chemistry, Vol. 19, Iss. 26, 2012-09 ,pp. : 4399-4413

Bentham Science Publishers

Access to resources Recommend Favorite

Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors

By Njar V.C.O.  

Drugs, Vol. 58, Iss. 2, 1999-08 ,pp. : 233-255

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology of MAO Inhibitors: Safety and Future

By Yamada M.   Yasuhara H.  

Neurotoxicology, Vol. 25, Iss. 1, 2004-01 ,pp. : 215-221

Elsevier

Access to resources Recommend Favorite